Cavendish NanoTherapeutics (CNT) is developing and marketing advanced therapeutic systems to aid the eradication of cancerous tumours in a targeted manner. CNT's systems utilise magnetic nanoparticles loaded with therapeutic agents which are directed and guided towards solid tumours. The cancer cells are killed by the combined action of targeted drug delivery and an increase in the local and regional temperature in the area around the tumours (hyperthermia).
The aim is to avoid most side effects and deliver the therapy precisely where it is needed, i.e. directly to the tumour site, thereby minimising any side effects. Higher doses of chemotherapy drugs can therefore reach the target area, even if a lower overall dose is administered to the patients.
CNT's disruptive technology is platform with wide applicability across numerous types of cancers. Preliminary and pilot clinical trials have shown an impressive 50-70% increase (on average) of the survival rates and/or reduction in the size of tumours.
CNT is developing and offering two main products. The first generation system (MagTherm™) utilises electromagnetic irradiation to induce regional hyperthermia and can be available for investigatory purposes, until fully CE marked and approved by the regulatory bodies. The second generation system (NanoMagTherm™) is under development and utilises the magnetic nanoparticles in conjunction with the first generation system to deliver superior treatment based on the combination of targeted drug delivery and hyperthermia.
The company is affiliated with the Cavendish Laboratory, University of Cambridge.
© Cavendish NanoTherapeutics, 2011
